JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB167921

Recombinant Human UBE2W protein

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human UBE2W protein is a Human Full Length protein, in the 1 to 159 aa range, expressed in Escherichia coli, with >75%, suitable for SDS-PAGE, WB.

View Alternative Names

UBC16, UBE2W, Ubiquitin-conjugating enzyme E2 W, E2 ubiquitin-conjugating enzyme W, N-terminal E2 ubiquitin-conjugating enzyme, N-terminus-conjugating E2, Ubiquitin carrier protein W, Ubiquitin-conjugating enzyme 16, Ubiquitin-protein ligase W, UBC-16

1 Images
SDS-PAGE - Recombinant Human UBE2W protein (AB167921)
  • SDS-PAGE

Unknown

SDS-PAGE - Recombinant Human UBE2W protein (AB167921)

SDS-PAGE analysis of ab167921.

Key facts

Purity

>75% Densitometry

Expression system

Escherichia coli

Tags

GST tag N-Terminus

Applications

SDS-PAGE, WB

applications

Biologically active

No

Accession

Q96B02

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 7.5 Constituents: 25% Glycerol (glycerin, glycerine), 0.79% Tris HCl, 0.31% Glutathione, 0.29% Sodium chloride, 0.004% (R*,R*)-1,4-Dimercaptobutan-2,3-diol, 0.003% EDTA, 0.002% PMSF

storage-buffer

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column
style
left-column
style
left-column

Sequence info

[{"sequence":"MASMQKRLQKELLALQNDPSPGMTLNEKSAQNSITQWIVDMESAPGTLYEGEKFQLLFKFSSRYPFDSPQVMFTGENIPVHPHVYSNGHICLSILTEDWSPALSVQSVCLSIISMLSSCKEKRRPPDNSFYVRTCNKNPKKTKWWYHELKSAFILSITD","proteinLength":"Full Length","predictedMolecularWeight":"45 kDa","actualMolecularWeight":null,"aminoAcidEnd":159,"aminoAcidStart":1,"nature":"Recombinant","expressionSystem":"Escherichia coli","accessionNumber":"Q96B02","tags":[{"tag":"GST","terminus":"N-Terminus"}]}]
style
left-column

Properties and storage information

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

UBE2W also known as Ubiquitin Conjugating Enzyme E2 W is an enzyme that plays a critical role in the ubiquitination process. It carries out the initial step of attaching ubiquitin to substrate proteins often working alongside E3 ligases. The enzyme has a mass of approximately 23 kDa. Expression of UBE2W is found in various tissues including the brain liver and muscles suggesting a broad functional role in cellular processes.
Biological function summary

UBE2W participates in the modification and degradation of proteins an essential mechanism in maintaining proteostasis. This enzyme is not typically part of a larger multiprotein complex acting independently to modify proteins by attaching ubiquitin monomers. UBE2W’s activity regulates protein stability and function influencing cell cycle progression and signal transduction mechanisms.

Pathways

The ubiquitin-proteasome pathway highlights the primary context in which UBE2W operates. This pathway is critical for protein degradation and involves cooperation with proteins such as E3 ubiquitin ligases and the proteasome complex. UBE2W collaborates closely with other ubiquitin enzymes including ubiquitin-activating (E1) enzymes to facilitate efficient protein turnover and regulation ensuring proper cellular homeostasis.

UBE2W's function affects cancer and neurodegenerative disorders. Alterations in the activity of UBE2W can lead to aberrant protein accumulation which is a characteristic in some cancer types and neurodegenerative diseases like Alzheimer's. Protein interactions between UBE2W and defective proteins accumulating in these conditions suggest that targeting UBE2W activity could have therapeutic potential in managing protein homeostasis-related diseases.
style
left-column

Specifications

Form

Liquid

style
left-column

General info

Function

Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins (PubMed : 20061386, PubMed : 21229326). Specifically monoubiquitinates the N-terminus of various substrates, including ATXN3, MAPT/TAU, POLR2H/RPB8 and STUB1/CHIP, by recognizing backbone atoms of disordered N-termini (PubMed : 23560854, PubMed : 23696636, PubMed : 25436519). Involved in degradation of misfolded chaperone substrates by mediating monoubiquitination of STUB1/CHIP, leading to recruitment of ATXN3 to monoubiquitinated STUB1/CHIP, and restriction of the length of ubiquitin chain attached to STUB1/CHIP substrates by ATXN3. After UV irradiation, but not after mitomycin-C (MMC) treatment, acts as a specific E2 ubiquitin-conjugating enzyme for the Fanconi anemia complex by associating with E3 ubiquitin-protein ligase FANCL and catalyzing monoubiquitination of FANCD2, a key step in the DNA damage pathway (PubMed : 19111657, PubMed : 21229326). In vitro catalyzes 'Lys-11'-linked polyubiquitination. UBE2W-catalyzed ubiquitination occurs also in the presence of inactive RING/U-box type E3s, i.e. lacking the active site cysteine residues to form thioester bonds with ubiquitin, or even in the absence of E3, albeit at a slower rate (PubMed : 25436519).

Sequence similarities

Belongs to the ubiquitin-conjugating enzyme family.

Post-translational modifications

Autoubiquitinated at Met-1.

Subcellular localisation

Nucleus

style
left-column

Product protocols

style
left-column

Target data

Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins (PubMed : 20061386, PubMed : 21229326). Specifically monoubiquitinates the N-terminus of various substrates, including ATXN3, MAPT/TAU, POLR2H/RPB8 and STUB1/CHIP, by recognizing backbone atoms of disordered N-termini (PubMed : 23560854, PubMed : 23696636, PubMed : 25436519). Involved in degradation of misfolded chaperone substrates by mediating monoubiquitination of STUB1/CHIP, leading to recruitment of ATXN3 to monoubiquitinated STUB1/CHIP, and restriction of the length of ubiquitin chain attached to STUB1/CHIP substrates by ATXN3. After UV irradiation, but not after mitomycin-C (MMC) treatment, acts as a specific E2 ubiquitin-conjugating enzyme for the Fanconi anemia complex by associating with E3 ubiquitin-protein ligase FANCL and catalyzing monoubiquitination of FANCD2, a key step in the DNA damage pathway (PubMed : 19111657, PubMed : 21229326). In vitro catalyzes 'Lys-11'-linked polyubiquitination. UBE2W-catalyzed ubiquitination occurs also in the presence of inactive RING/U-box type E3s, i.e. lacking the active site cysteine residues to form thioester bonds with ubiquitin, or even in the absence of E3, albeit at a slower rate (PubMed : 25436519).
See full target information UBE2W
style
left-column
style
left-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions
style
left-column
style
right-column
style
bg-slate-100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com